(VIANEWS) – The NASDAQ ended the session with Arcturus Therapeutics (ARCT) rising 6.29% to $14.86 on Friday while NASDAQ slid 1.51% to $10,575.62.

Arcturus Therapeutics’s last close was $13.98, 72.9% under its 52-week high of $51.58.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc. is an RNA medicines firm that focuses on vaccine development for rare infections, liver diseases, and other respiratory illnesses in the United States. LUNAR -OTC is the company’s program to develop ornithine transcarbamylase deficiency (OTC); and LUNAR -CF for cystic fibrosis lung diseases caused by mutations of cystic fibrosis Transmembrane Conductance Regulator (CFTR). Other vaccine programs include LUNAR -COV19, and LUNAR -FLU. Vinbiocare Biotechnology Joint Stock Company manufactures COVID-19 vaccines. Janssen Pharmaceuticals, Inc. develops nucleic-acid-based therapeutic candidates to treat hepatitis B viruses. Ultragenyx Pharmaceutical, Inc. develops mRNA therapeutic candidate candidates to treat rare diseases. CureVac AG develops mRNA vaccine and therapeutic candidates to various indications. The LUNAR-COV19 vaccine will be developed by the Singapore Economic Development Board, Duke-NUS Medical School, and Millennium Pharmaceuticals, Inc. It was established in San Diego in 2013.

Earnings Per Share

As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $-3.55.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -73.88%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 8.2% and 13.7%, respectively.

Yearly Top and Bottom Value

Arcturus Therapeutics’s stock is valued at $14.86 at 18:17 EST, way under its 52-week high of $51.58 and way above its 52-week low of $11.70.

More news about Arcturus Therapeutics (ARCT).


Please enter your comment!
Please enter your name here